Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants
Latest Information Update: 07 Nov 2022
Price :
$35 *
At a glance
- Drugs Milvexian (Primary)
- Indications Stroke; Thrombosis; Venous thromboembolism
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 27 Sep 2022 Results presented at the 2022 American College of Clinical Pharmacology Annual Meeting
- 13 Aug 2019 Status changed from not yet recruiting to completed.
- 10 May 2019 New trial record